Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Tract Infections 1Urinary Bladder Neoplasms 1Surgical Wound Infection 1Skin Neoplasms 1Neoplasms 1Lung Neoplasms 1Inflammation 1Infections 1Head and Neck Neoplasms 1Exanthema 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Clindamycin × Clear all
NCT06120140 2026-06-05

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡